Category Archives: Central and Eastern Europe

Replicor discloses long term functional control of HBV and HDV infection in high proportions of treated patients at EASL 2018

Posted on April 16, 2018 by

Below, we are re-publishing with permission the press-release issued by Replicor on the 13th of April 2018 MONTREAL, April 13, 2018 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic … Continue reading →

Posted in Central and Eastern Europe, ClinAccel.Net, Clinical Accelerator, Conferences | Leave a comment

Clinical Accelerator announces collaboration with VisCardia for investigating a novel device therapy for chronic heart failure

Posted on December 11, 2017 by

Kiev, Ukraine – December 11, 2017: Clinical Accelerator, a full-service clinical contract research organization, is pleased to announce it has entered into a collaboration with VisCardia Inc. for conducting clinical studies for its VisONE medical device in the Ukraine. The … Continue reading →

Posted in Central and Eastern Europe, ClinAccel.Net, Clinical Accelerator | Leave a comment

Promising Interim Clinical Data for NOX66

Posted on November 20, 2017 by

Below, we are re-publishing with permission the press-release issued by Noxopharm Limited on the 20th of November 2017 PROMISING INTERIM CLINICAL DATA FOR NOX66 Patients with metastatic, late-stage cancers 10 of 11 patients showing no disease progression following 3-months treatment with NOX66 … Continue reading →

Posted in Central and Eastern Europe, Clinical Accelerator | Leave a comment

REPLICOR’S NEW PHASE II TRIAL CONDUCTED BY CLINICAL ACCELERATOR PRODUCES EXCITING CLINICAL DATA FOR THEIR NUCLEIC ACID POLYMER (NAP) DRUG REP 2139-CA FOR PATIENTS WITH HBV / HDV CO-INFECTION.

Posted on May 18, 2015 by

In December last year a Clinical Accelerator post (1) reported that recruitment was underway in Moldova for an interesting Phase II trial of Replicor’s novel nucleic acid polymer (NAP), REP 2139-Ca, in combination with the immunotherapeutic agent, pegylated interferon alfa-2a … Continue reading →

Posted in Central and Eastern Europe, Clinical Accelerator | Leave a comment

IQPC finally recognizes the value of Eastern Europe for clinical trials

Posted on March 30, 2015 by

You don’t say! Packed with eager, treatment naive participants, and short of the many transportation complexities faced in little established research sites, Eastern Europe is becoming increasingly recognised as among the best places to conduct a clinical trial. The surprise … Continue reading →

Posted in Central and Eastern Europe | Leave a comment

Completion of D-Pharm’s Phase II trial for stroke patients in Ukraine

Posted on December 15, 2014 by

Clinical Accelerator is pleased to announce the timely completion of an interesting trial it has been conducting for D-Pharm in patients with ischaemic stroke at the State Medical Preventive Institution “Central Clinical Hospital of Ukrzaliznytsia”, Kharkov, Ukraine (1). This study … Continue reading →

Posted in Central and Eastern Europe, Clinical Accelerator | Leave a comment

Clinical trials in Poland

Posted on November 4, 2014 by

At Clinical Accelerator we conduct many of our trials in Central and Eastern Europe, and it’s important to us that we monitor the latest data coming for our countries of operation. We’re pleased to see that, based on recent statistics, … Continue reading →

Posted in Central and Eastern Europe | Leave a comment